(A) EFS for the overall study population for the start of therapy. (B) OS for overall study population from the start of therapy. (C) EFS stratified by interim PET results. (D) EFS stratified by EOT PET results. (E) Spider plot of ctDNA allele frequency from start of therapy through EOT stratified by patients with or without known progressive disease. (F) EFS stratified by detection of ctDNA at the EOT.